{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:03:25Z","timestamp":1784822605108,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40120-026-00961-9","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:15:04Z","timestamp":1779174904000},"page":"1763-1775","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy, Safety, and Tolerability of Atogepant in Migraine Patients from the UAE"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7513-5706","authenticated-orcid":false,"given":"Taoufik","family":"Alsaadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9607-3353","authenticated-orcid":false,"given":"Reem","family":"Suliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahsan H.","family":"Khandoker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam Nasser","family":"Aljaafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghaith","family":"Alsabbagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Saidam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Hamoulila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"4","key":"961_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","volume":"23","author":"GBD 2021 Nervous System Disorders Collaborators","year":"2024","unstructured":"GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024;23(4):344\u201381. https:\/\/doi.org\/10.1016\/S1474-4422(24)00038-3.","journal-title":"Lancet Neurol"},{"issue":"1","key":"961_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137. https:\/\/doi.org\/10.1186\/s10194-020-01208-0.","journal-title":"J Headache Pain"},{"issue":"8","key":"961_CR3","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17(8):501\u201314. https:\/\/doi.org\/10.1038\/s41582-021-00509-5.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"961_CR4","doi-asserted-by":"publisher","first-page":"100122","DOI":"10.1016\/j.neurop.2023.100122","volume":"3","author":"I Unal-Cevik","year":"2023","unstructured":"Unal-Cevik I, Arslan D. Similarities and differences between migraine and other types of headaches: migraine mimics. Neurol Perspect. 2023;3(2):100122. https:\/\/doi.org\/10.1016\/j.neurop.2023.100122.","journal-title":"Neurol Perspect"},{"issue":"1","key":"961_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s10194-024-01889-x","volume":"25","author":"A Raggi","year":"2024","unstructured":"Raggi A, Leonardi M, Arruda M, et al. Hallmarks of primary headache: part 1 - migraine. J Headache Pain. 2024;25(1):189. https:\/\/doi.org\/10.1186\/s10194-024-01889-x.","journal-title":"J Headache Pain"},{"issue":"8","key":"961_CR6","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/head.13613","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse DC, Fanning KM, Reed ML, et al. Life with migraine: effects on relationships, career, and finances from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache. 2019;59(8):1286\u201399. https:\/\/doi.org\/10.1111\/head.13613.","journal-title":"Headache"},{"issue":"5","key":"961_CR7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S0025-6196(11)60561-2","volume":"84","author":"DC Buse","year":"2009","unstructured":"Buse DC, Rupnow MFT, Lipton RB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc. 2009;84(5):422\u201335. https:\/\/doi.org\/10.1016\/S0025-6196(11)60561-2.","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"961_CR8","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/head.14824","volume":"64","author":"J Ailani","year":"2024","unstructured":"Ailani J, Gandhi P, Lalla A, et al. Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine. Headache. 2024;64(10):1253\u201363. https:\/\/doi.org\/10.1111\/head.14824.","journal-title":"Headache"},{"issue":"S2","key":"961_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/head.12505_2","volume":"55","author":"RB Lipton","year":"2015","unstructured":"Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015;55(S2):103\u201322. https:\/\/doi.org\/10.1111\/head.12505_2.","journal-title":"Headache"},{"issue":"1","key":"961_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202.","journal-title":"Cephalalgia"},{"issue":"2","key":"961_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251320608","volume":"45","author":"S Sacco","year":"2025","unstructured":"Sacco S, Ashina M, Diener HC, et al. Setting higher standards for migraine prevention: a position statement of the International Headache Society. Cephalalgia. 2025;45(2):03331024251320608. https:\/\/doi.org\/10.1177\/03331024251320608.","journal-title":"Cephalalgia"},{"issue":"7","key":"961_CR12","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS, Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021\u201339. https:\/\/doi.org\/10.1111\/head.14153.","journal-title":"Headache"},{"issue":"1","key":"961_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s10194-024-01783-6","volume":"25","author":"RB Lipton","year":"2024","unstructured":"Lipton RB, Nahas SJ, Pozo-Rosich P, et al. Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial. J Headache Pain. 2024;25(1):83. https:\/\/doi.org\/10.1186\/s10194-024-01783-6.","journal-title":"J Headache Pain"},{"issue":"6","key":"961_CR14","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478\u201388. https:\/\/doi.org\/10.1177\/0333102414547138.","journal-title":"Cephalalgia"},{"issue":"6","key":"961_CR15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338\u201350. https:\/\/doi.org\/10.1038\/s41582-018-0003-1.","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"961_CR16","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/jnnp-2020-324674","volume":"92","author":"JC Ray","year":"2021","unstructured":"Ray JC, Kapoor M, Stark RJ, et al. Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects. J Neurol Neurosurg Psychiatry. 2021;92(12):1325\u201334. https:\/\/doi.org\/10.1136\/jnnp-2020-324674.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"961_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00435","author":"B Gao","year":"2020","unstructured":"Gao B, Sun N, Yang Y, et al. Safety and efficacy of fremanezumab for the prevention of migraine: a meta-analysis from randomized controlled trials. Front Neurol. 2020. https:\/\/doi.org\/10.3389\/fneur.2020.00435.","journal-title":"Front Neurol"},{"issue":"1","key":"961_CR18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s10194-025-02087-z","volume":"26","author":"FM Amin","year":"2025","unstructured":"Amin FM, Linnet T, Cullum CK, Do TP, Younis S. Tolerability of switch from erenumab to fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, real-world, observational study. J Headache Pain. 2025;26(1):152. https:\/\/doi.org\/10.1186\/s10194-025-02087-z.","journal-title":"J Headache Pain"},{"issue":"12","key":"961_CR19","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.3390\/brainsci12121612","volume":"12","author":"JP Rissardo","year":"2022","unstructured":"Rissardo JP, Caprara ALF. Gepants for acute and preventive migraine treatment: a narrative review. Brain Sci. 2022;12(12):1612. https:\/\/doi.org\/10.3390\/brainsci12121612.","journal-title":"Brain Sci"},{"issue":"5","key":"961_CR20","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/head.13791","volume":"60","author":"D Tepper","year":"2020","unstructured":"Tepper D. Gepants. Headache. 2020;60(5):1037\u20139. https:\/\/doi.org\/10.1111\/head.13791.","journal-title":"Headache"},{"issue":"22","key":"961_CR21","doi-asserted-by":"publisher","first-page":"6713","DOI":"10.3390\/jcm13226713","volume":"13","author":"AS Alrasheed","year":"2024","unstructured":"Alrasheed AS, Almaqboul TM, Alshamrani RA, AlMohish NM, Alabdali MM. Safety and efficacy of atogepant for the preventive treatment of migraines in adults: a systematic review and meta-analysis. J Clin Med. 2024;13(22):6713. https:\/\/doi.org\/10.3390\/jcm13226713.","journal-title":"J Clin Med"},{"issue":"1","key":"961_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40265-021-01644-5","volume":"82","author":"ED Deeks","year":"2022","unstructured":"Deeks ED. Atogepant: first approval. Drugs. 2022;82(1):65\u201370. https:\/\/doi.org\/10.1007\/s40265-021-01644-5.","journal-title":"Drugs"},{"issue":"1","key":"961_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/head.14439","volume":"63","author":"M Ashina","year":"2023","unstructured":"Ashina M, Tepper SJ, Reuter U, et al. Once-daily oral atogepant for the long-term preventive treatment of migraine: findings from a multicenter, randomized, open-label, phase\u00a03 trial. Headache. 2023;63(1):79\u201388. https:\/\/doi.org\/10.1111\/head.14439.","journal-title":"Headache"},{"issue":"10404","key":"961_CR24","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S0140-6736(23)01049-8","volume":"402","author":"P Pozo-Rosich","year":"2023","unstructured":"Pozo-Rosich P, Ailani J, Ashina M, et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet. 2023;402(10404):775\u201385. https:\/\/doi.org\/10.1016\/S0140-6736(23)01049-8.","journal-title":"Lancet"},{"issue":"4","key":"961_CR25","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(24)00025-5","volume":"23","author":"C Tassorelli","year":"2024","unstructured":"Tassorelli C, Nagy K, Pozo-Rosich P, et al. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase\u00a03b trial. Lancet Neurol. 2024;23(4):382\u201392. https:\/\/doi.org\/10.1016\/S1474-4422(24)00025-5.","journal-title":"Lancet Neurol"},{"issue":"1","key":"961_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/03331024211042385","volume":"42","author":"TJ Schwedt","year":"2022","unstructured":"Schwedt TJ, Lipton RB, Ailani J, et al. Time course of efficacy of atogepant for the preventive treatment of migraine: results from the randomized, double-blind ADVANCE trial. Cephalalgia. 2022;42(1):3\u201311. https:\/\/doi.org\/10.1177\/03331024211042385.","journal-title":"Cephalalgia"},{"issue":"S4","key":"961_CR27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/head.12601","volume":"55","author":"C Cameron","year":"2015","unstructured":"Cameron C, Kelly S, Hsieh SC, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache. 2015;55(S4):221\u201335. https:\/\/doi.org\/10.1111\/head.12601.","journal-title":"Headache"},{"issue":"8","key":"961_CR28","doi-asserted-by":"publisher","first-page":"333102423119029","DOI":"10.1177\/03331024231190296","volume":"51","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Halker Singh RB, Mechtler L, et al. Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial. Cephalalgia. 2023;51(8):3331024231190296. https:\/\/doi.org\/10.1177\/03331024231190296.","journal-title":"Cephalalgia"},{"issue":"4","key":"961_CR29","doi-asserted-by":"publisher","first-page":"333102425133592","DOI":"10.1177\/03331024251335927","volume":"45","author":"F Vernieri","year":"2025","unstructured":"Vernieri F, Iannone LF, Lo Castro F, et al. Effectiveness and tolerability of atogepant in the prevention of migraine: a real life, prospective, multicentric study (the STAR study). Cephalalgia. 2025;45(4):3331024251335927. https:\/\/doi.org\/10.1177\/03331024251335927.","journal-title":"Cephalalgia"},{"issue":"1","key":"961_CR30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s10194-025-02068-2","volume":"26","author":"P Barbanti","year":"2025","unstructured":"Barbanti P, Egeo G, Pistoia F, et al. GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures. J Headache Pain. 2025;26(1):122. https:\/\/doi.org\/10.1186\/s10194-025-02068-2.","journal-title":"J Headache Pain"},{"issue":"10","key":"961_CR31","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/AJP.0000000000001136","volume":"39","author":"W Sun","year":"2023","unstructured":"Sun W, Cheng H, Xia B, et al. Comparative efficacy and safety of five anti-calcitonin gene-related peptide agents for migraine prevention: a network meta-analysis. Clin J Pain. 2023;39(10):560\u20139. https:\/\/doi.org\/10.1097\/AJP.0000000000001136.","journal-title":"Clin J Pain"},{"issue":"8","key":"961_CR32","doi-asserted-by":"publisher","first-page":"333102425136520","DOI":"10.1177\/03331024251365206","volume":"45","author":"S Ashina","year":"2025","unstructured":"Ashina S, Ashina M, Holle-Lee D, et al. Long-term safety, efficacy and functional outcomes of atogepant for the preventive treatment of migraine. Cephalalgia. 2025;45(8):3331024251365206. https:\/\/doi.org\/10.1177\/03331024251365206.","journal-title":"Cephalalgia"},{"issue":"1","key":"961_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40122-024-00686-3","volume":"14","author":"T Alsaadi","year":"2025","unstructured":"Alsaadi T, Al Madani A, Alhatou M, et al. Prevalence, treatment, and unmet needs of migraine in the Middle East: a systematic review. Pain Ther. 2025;14(1):145\u201383. https:\/\/doi.org\/10.1007\/s40122-024-00686-3.","journal-title":"Pain Ther"},{"issue":"9","key":"961_CR34","doi-asserted-by":"publisher","first-page":"333102425137456","DOI":"10.1177\/03331024251374569","volume":"45","author":"Y Matsumori","year":"2025","unstructured":"Matsumori Y, Yamada H, Nagaseki Y, et al. Atogepant for the preventive treatment of episodic migraine in Japanese participants: a phase\u00a02\/3, randomized, double-blind, placebo-controlled trial with an active treatment extension (RELEASE). Cephalalgia. 2025;45(9):3331024251374569. https:\/\/doi.org\/10.1177\/03331024251374569.","journal-title":"Cephalalgia"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00961-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00961-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00961-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:33Z","timestamp":1784819493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00961-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["961"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00961-9","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Taoufik Alsaadi, Reem Suliman, Mariam Nasser Aljaafari, Ghaith Alsabbagh, Mohammad Saidam, Khaled Hamoulila, and Ahsan Khandoker declare that they have no competing interests and nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research was conducted in accordance with the Declaration of Helsinki and consistent with Good Clinical Practice (GCP) and the applicable regulatory requirements. The American Center for Psychiatry and Neurology (ACPN) Institutional Review Board has waived the need for informed consent for this study (reference number ACPN_IRB_0075) as it involved a retrospective analysis.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}